(NP (NP (NN Demonstration)) (PP (IN of) (NP (NP-COOD (NP (NP-COOD (NP (NN estrogen)) (CC and) (NP (NN progesterone))) (NNS receptors)) (CONJP (RB as) (RB well) (IN as)) (NP (NP-COOD (NP (NN Ki-67)) (CC and) (NP (NN p-145))) (NNS antigens))) (PP (IN in) (NP (NP (JJ single) (NN tumor) (NNS cells)) (PP (IN from) (NP (UCP-COOD (NP (NN blood)) (CC and) (ADJP (JJ pleural))) (NNS effusions))))))) (VP (VBG using) (NP (DT a) (NN slide) (NN assay))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN slide) (NN assay)) (SBAR (WHNP-53 (WDT that)) (S (NP-SBJ (-NONE- *T*-53)) (VP (VBZ allows) (NP (NP (DT the) (NN demonstration)) (PP (IN of) (NP (NP (NNS antigens)) (ADJP (JJ localized) (PP (IN in) (NP (NP (DT the) (NN nucleus)) (PP-COOD (PP (IN from) (NP (VBN isolated) (JJ white) (NN blood) (NNS cells))) (CONJP (RB as) (RB well) (IN as)) (PP (IN from) (NP (NP (JJ single) (NN tumor) (NNS cells)) (VP (VBN derived) (NP (-NONE- *)) (PP (IN from) (NP (JJ malignant) (NNS effusions)))))))))))))))))) (. .))
(S (PP (IN With) (NP (DT the) (NNS antibodies) (NP-COOD (NP (NN Ki-67)) (CC and) (NP (NN anti-p-145))))) (NP-SBJ (NP (DT an) (VBN increased) (NN rate)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ nuclear)) (CC and) (ADJP (JJ nucleolar))) (NN staining)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS cells)) (PP (IN from) (NP (ADJP (RB highly) (JJ malignant)) (NNS lymphomas)))))) (. .))
(S (NP-SBJ-54 (DT An) (ADJP (RB almost) (JJ identical)) (NN reaction)) (VP (VBD was) (VP (VBN obtained) (NP (-NONE- *-54)) (SBAR-TMP (WHADVP-104 (WRB when)) (S (NP-SBJ-55 (NP (NN tumor) (NNS cells)) (PP (IN from) (NP (JJ malignant) (NNS effusions)))) (VP (VBD were) (VP (VBN tested) (NP (-NONE- *-55)) (ADVP (-NONE- *T*-104)))))))) (. .))
(S (NP-SBJ (NP (NNS Cells)) (VP (VBN isolated) (NP (-NONE- *)) (PP (IN from) (NP (NP (DT the) (NN blood)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ leukemic) (NN spread)) (PP (IN of) (NP (NP (NNS lymphomas)) (PP (IN of) (NP (JJ low) (NN malignancy))))))))))))) (VP (VBD yielded) (NP (NP (DT a) (JJ weak) (NN staining)) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ normal) (JJ mesothelial) (NNS cells)) (PP (IN from) (NP (JJ non-tumorous) (NN cavity) (NNS fluids)))))))))) (. .))
(S (NP-SBJ-56 (NP (DT The) (NN detection)) (PP (IN of) (NP (NP (NP (NP-COOD (NP (NN estrogen)) (CC and) (NP (NN progesterone))) (NNS receptors)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN ER)) (CC and) (NP (NN PR))) (-RRB- -RRB-))) (ADJP (JJ localized) (PP (IN in) (NP (DT the) (NN cell) (NN nucleus))))))) (VP (MD can) (VP (VB be) (VP (VBN achieved) (NP (-NONE- *-56)) (PP (IN by) (NP (DT the) (JJ same) (NN assay)))))) (. .))
(S (NP-SBJ-57 (DT The) (NN reaction)) (VP (VBZ is) (VP (VBN enhanced) (NP (-NONE- *-57)) (PP (IN by) (NP-LGS (NP (NN incubation)) (PP (IN of) (NP (DT the) (NN tumor) (NNS cells))) (PP-TMP (IN for) (NP (CD 30) (NN min))) (PP (IN at) (NP (CD 37) (NNS degrees) (NN C))) (PP (RB prior) (TO to) (NP (NN fixation))))))) (. .))
(S (NP-SBJ-58 (NP (JJ Pleural) (NNS effusions)) (PP (IN from) (NP (NP (CD 20) (NNS patients)) (PP (IN with) (NP (NN breast) (NN cancer)))))) (VP (VBD were) (VP (VBN tested) (NP (-NONE- *-58)))) (. .))
(S-COOD (S (NP-SBJ (NN ER)) (VP (VBD was) (ADJP-PRD (JJ positive)) (PP (IN in) (NP (CD 13))))) (CC and) (S (NP-SBJ (NN PR)) (VP (VBD was) (ADJP-PRD (JJ positive)) (PP (IN in) (NP (NP (CD 12)) (PP (IN of) (NP (DT the) (CD 20) (NNS samples))))))) (. .))
(S (PP (IN In) (NP (CD 5) (NNS cases))) (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (NP (DT a) (JJ divergent) (NN reaction)) (PP (IN with) (NP (NP-COOD (NP (NN ER)) (CC and) (NP (NN PR))) (NN antibody))))) (. .))
(S (NP-SBJ-59 (NP (DT The) (NN hormone) (NNS receptors)) (PP (IN of) (NP (DT the) (JJ primary) (NN tumor)))) (VP (VBD were) (VP (VBN known) (NP (-NONE- *-59)) (PP (IN in) (NP (NP-COOD (NP (CD 15) (PRN (-LRB- -LRB-) (NP (NN ER)) (-RRB- -RRB-)) (NP (-NONE- *RNR*-60))) (CC and) (NP (CD 14) (PRN (-LRB- -LRB-) (NP (NN PR)) (-RRB- -RRB-)) (NP (-NONE- *RNR*-60)))) (NP-60 (NNS patients)))) (, ,) (ADVP (RB respectively)))) (. .))
(S (PP (IN In) (NP (DT each) (NN cohort))) (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (NP (QP (RB only) (CD one)) (NN case)) (PP (IN with) (NP-COOD (NP (NP (DT a) (JJ negative) (NN reaction)) (PP (IN of) (NP (DT the) (JJ primary) (NN tumor)))) (CC and) (NP (NP (DT a) (JJ positive) (NN reaction)) (PP (IN with) (NP (NP (DT the) (VBN isolated) (NN tumor) (NNS cells)) (PP (IN from) (NP (DT the) (JJ pleural) (NNS effusions)))))))))) (. .))
(S (NP-SBJ (DT These) (NNS results)) (VP (VBP indicate) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN demonstration)) (PP (IN of) (NP (NP (NN hormone) (NN receptor) (NNS proteins)) (PP (IN in) (NP (NP (NNS cells)) (PP (IN from) (NP (JJ malignant) (NNS effusions)))))))) (VP (VBZ is) (ADJP-PRD (JJ possible))))) (CC and) (SBAR (IN that) (S (NP-SBJ (EX there)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN correlation)) (PP (IN with) (NP (NP (DT the) (NN status)) (PP (IN of) (NP (NP (DT the) (JJ primary) (NN site)) (PP (IN of) (NP (NN cancer))))))))))))) (. .))
